J Karpakis1, H Rabie, J Howard, A Janse van Rensburg, M F Cotton. 1. Children's Infectious Diseases Clinical Research Unit, Department of Paediatrics and Child Health, Tygerberg Children's Hospital and Stellenbosch University, W Cape.
Abstract
BACKGROUND: Chronic otorrhoea occurs commonly in HIV-infected children. However, there are few data on incidence and severity. OBJECTIVE: To document the prevalence of otorrhoea in the clinic attendees. METHODS: A retrospective chart review was done of all HIVI infected children seen at the Family Clinic for HIV from 1 February 1997 to 31 December 2001, a period preceding widespread availability of antiretrovirals. Otorrhoea was classified into two groups, viz. group 1 (mild): an episode lasting less than 1 month, and group 2 (severe): an episode lasting more than 1 month or more than 1 episode of otorrhoea. The clinical and immune stages of the children were noted. RESULTS: Of 326 children seen during the study period, 104 (32%) had otorrhoea. Forty-five (13.8%) had mild and 59 (18.1%) severe otorrhoea. Two hundred and eighty-eight (88.6%) had either Centers for Disease Control stage B or C disease. The median CD4 percentage in children with otorrhoea was 17.5% (8.3-23%) versus 21% (14-28%) in those without otorrhoea (p=0.004). The odds ratio (OR) of children in stage B or C not having severe otorrhoea was 0.1 (0.01 - 0.72, p = 0.013). The OR for immune class 2 or 3 without severe otorrhoea was 0.39 (0.18 - 0.85, p = 0.021). CONCLUSIONS: Otorrhoea contributes to the morbidity of HIV infection in children. It is a marker for symptomatic disease and CD4 depletion and should be included in clinical classifications.
BACKGROUND:Chronic otorrhoea occurs commonly in HIV-infectedchildren. However, there are few data on incidence and severity. OBJECTIVE: To document the prevalence of otorrhoea in the clinic attendees. METHODS: A retrospective chart review was done of all HIVI infectedchildren seen at the Family Clinic for HIV from 1 February 1997 to 31 December 2001, a period preceding widespread availability of antiretrovirals. Otorrhoea was classified into two groups, viz. group 1 (mild): an episode lasting less than 1 month, and group 2 (severe): an episode lasting more than 1 month or more than 1 episode of otorrhoea. The clinical and immune stages of the children were noted. RESULTS: Of 326 children seen during the study period, 104 (32%) had otorrhoea. Forty-five (13.8%) had mild and 59 (18.1%) severe otorrhoea. Two hundred and eighty-eight (88.6%) had either Centers for Disease Control stage B or C disease. The median CD4 percentage in children with otorrhoea was 17.5% (8.3-23%) versus 21% (14-28%) in those without otorrhoea (p=0.004). The odds ratio (OR) of children in stage B or C not having severe otorrhoea was 0.1 (0.01 - 0.72, p = 0.013). The OR for immune class 2 or 3 without severe otorrhoea was 0.39 (0.18 - 0.85, p = 0.021). CONCLUSIONS: Otorrhoea contributes to the morbidity of HIV infection in children. It is a marker for symptomatic disease and CD4 depletion and should be included in clinical classifications.
Authors: Clotilde Hainline; Reghana Taliep; Gill Sorour; Sharon Nachman; Helena Rabie; Els Dobbels; Anita Janse van Rensburg; Morna Cornell; Avy Violari; Shabir A Madhi; Mark F Cotton Journal: BMC Res Notes Date: 2011-10-26
Authors: Martha F Mushi; Alfred E Mwalutende; Japhet M Gilyoma; Phillipo L Chalya; Jeremiah Seni; Mariam M Mirambo; Stephen E Mshana Journal: BMC Ear Nose Throat Disord Date: 2016-01-07